Investment analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for shares of 89bio in a research note issued on Monday, June 6th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($2.83) per share for the year.
ETNB has been the subject of several other reports. Piper Sandler cut their price objective on 89bio from $54.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, May 17th. SVB Leerink cut their price objective on 89bio from $62.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, March 25th. Oppenheimer lowered their target price on 89bio from $49.00 to $40.00 in a report on Friday, May 13th. HC Wainwright lowered their target price on 89bio from $46.00 to $29.00 in a report on Thursday, May 12th. Finally, Raymond James upgraded 89bio from an “outperform” rating to a “strong-buy” rating and lowered their target price for the stock from $33.00 to $12.00 in a report on Thursday, May 12th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $34.88.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.